Skip to content
Study details
Enrolling now

Immunotherapy and Irreversible Electroporation for Advanced Pancreatic Cancer

University of Louisville
NCT IDNCT03080974ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

10

Study length

about 12 years

Ages

18+

Locations

1 site in KY

What this study is about

Researchers are testing whether irreversible electroporation, given together with Nivolumab, can help people with locally advanced pancreatic cancer. The trial will also look at how well this treatment works and if it causes any side effects.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Nivolumab
  • 2.Undergo Irreversible Electroporation

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)

Drug routes

infusion

Endpoints

Primary: Safety and Tolerability of Combination Irreversible Electroporation and Nivolumab Treatment

Secondary: Overall Survival, Progression Free Survival